DK1594868T3 - 8-aza-bicyclo[3.2.1]octanderivater og anvendelse deraf som monoamin-neurotransmitter-genoptagelsesinhibitorer - Google Patents

8-aza-bicyclo[3.2.1]octanderivater og anvendelse deraf som monoamin-neurotransmitter-genoptagelsesinhibitorer

Info

Publication number
DK1594868T3
DK1594868T3 DK04709633.4T DK04709633T DK1594868T3 DK 1594868 T3 DK1594868 T3 DK 1594868T3 DK 04709633 T DK04709633 T DK 04709633T DK 1594868 T3 DK1594868 T3 DK 1594868T3
Authority
DK
Denmark
Prior art keywords
aza
bicyclo
monoamine neurotransmitter
reuptake inhibitors
octane derivatives
Prior art date
Application number
DK04709633.4T
Other languages
Danish (da)
English (en)
Inventor
Dan Peters
Gunnar M Olsen
Jurgen Scheel-Krueger
Elsebet Ostergaard Nielsen
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Application granted granted Critical
Publication of DK1594868T3 publication Critical patent/DK1594868T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK04709633.4T 2003-02-12 2004-02-10 8-aza-bicyclo[3.2.1]octanderivater og anvendelse deraf som monoamin-neurotransmitter-genoptagelsesinhibitorer DK1594868T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200300213 2003-02-12
US44810603P 2003-02-20 2003-02-20
PCT/EP2004/050107 WO2004072071A1 (en) 2003-02-12 2004-02-10 8-aza-bicyclo (3.2.1) octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Publications (1)

Publication Number Publication Date
DK1594868T3 true DK1594868T3 (da) 2010-03-15

Family

ID=32870667

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04709633.4T DK1594868T3 (da) 2003-02-12 2004-02-10 8-aza-bicyclo[3.2.1]octanderivater og anvendelse deraf som monoamin-neurotransmitter-genoptagelsesinhibitorer

Country Status (12)

Country Link
US (1) US7247643B2 (enExample)
EP (1) EP1594868B1 (enExample)
JP (1) JP2006517568A (enExample)
AT (1) ATE448223T1 (enExample)
AU (1) AU2004212166B2 (enExample)
CA (1) CA2515584A1 (enExample)
DE (1) DE602004024033D1 (enExample)
DK (1) DK1594868T3 (enExample)
ES (1) ES2335664T3 (enExample)
MX (1) MXPA05008314A (enExample)
NZ (1) NZ541249A (enExample)
WO (1) WO2004072071A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500371A (ja) * 2001-08-08 2005-01-06 ニューロサーチ、アクティーゼルスカブ 置換されたアミン誘導体及びこれをモノアミン神経伝達物質再取り込み阻害剤として使用する方法
EP1779851A1 (en) * 2005-10-31 2007-05-02 Boehringer Ingelheim Pharma GmbH & Co.KG Treatment of diabetes
JP5194607B2 (ja) * 2006-07-26 2013-05-08 大正製薬株式会社 ソーシャルインターラクションの低下予防・改善剤
DE102007046887A1 (de) 2007-09-28 2009-04-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von (1R,5S)-Anhydroecgoninestersalzen
WO2009065845A1 (en) * 2007-11-20 2009-05-28 Neurosearch A/S A method for treating over-eating disorders
US8101642B2 (en) 2008-06-05 2012-01-24 Sk Biopharmaceuticals Co., Ltd. 3-substituted propanamine compounds
US8546576B2 (en) 2008-06-06 2013-10-01 Sk Biopharmaceuticals Co., Ltd. 3 or 4-substituted piperidine compounds
WO2010086612A1 (en) 2009-01-29 2010-08-05 Cambrex Karlskoga Ab Process for preparing enantiomerically enriched alkaloids
US9637470B2 (en) 2013-02-22 2017-05-02 Baylor College Of Medicine Treatment for substance use disorders and stress disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241481A (en) * 1991-02-04 1994-06-27 Hoechst Roussel Pharma Derivatives of 8-aza-bicyclo[3.2.1]octane and pharmaceutical compositions thereof
AU672052B2 (en) * 1992-12-23 1996-09-19 Neurosearch A/S Antidepressant and antiparkinsonian compounds
TR199800780T2 (xx) 1995-11-02 1998-07-21 Neurosearch A/S Kayna�m�� tropan t�revleri, haz�rlan��lar� ve kullan�mlar�.
ZA971525B (en) 1996-02-22 1997-10-21 Neurosearch As Tropane derivatives, their preparation and use.
WO1999065492A1 (en) * 1998-06-19 1999-12-23 Eli Lilly And Company Inhibition of serotonin reuptake
EP1358177B1 (en) * 2000-10-13 2006-08-02 NeuroSearch A/S Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
WO2002076440A2 (en) * 2001-03-23 2002-10-03 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
JP2005508872A (ja) * 2001-05-23 2005-04-07 ニューロサーチ、アクティーゼルスカブ トロパン誘導体及びこれをモノアミン神経伝達物質再取り込み阻害剤として使用する方法
EP1406900B1 (en) * 2001-07-06 2006-10-04 Neurosearch A/S Novel compounds, their preparation and use
JP2005500371A (ja) * 2001-08-08 2005-01-06 ニューロサーチ、アクティーゼルスカブ 置換されたアミン誘導体及びこれをモノアミン神経伝達物質再取り込み阻害剤として使用する方法

Also Published As

Publication number Publication date
NZ541249A (en) 2008-04-30
AU2004212166A1 (en) 2004-08-26
US7247643B2 (en) 2007-07-24
MXPA05008314A (es) 2005-10-05
DE602004024033D1 (de) 2009-12-24
CA2515584A1 (en) 2004-08-26
AU2004212166B2 (en) 2010-07-29
EP1594868B1 (en) 2009-11-11
ES2335664T3 (es) 2010-03-31
ATE448223T1 (de) 2009-11-15
JP2006517568A (ja) 2006-07-27
EP1594868A1 (en) 2005-11-16
WO2004072071A1 (en) 2004-08-26
US20060122218A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
WO2004113297A3 (en) Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
TW200510404A (en) Novel 8-aza-bicyclo[3.2.1] octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
UA94417C2 (ru) Замещенные 7-азаиндазолы, композиция, которая их содержит, и применение
TW200613243A (en) Novel compounds
DK1797088T3 (da) Hidtil ukendte chromen-2-on-derivater og anvendelse heraf som monoamin-neurotransmitter-genoptagelseshæmmere
MX2009005916A (es) Nuevos derivados de cromen-2-ona y su uso como inhibidores de la reabsorcion del neurotransmisor de monoamina.
TW200639156A (en) New compounds
TW200800980A (en) Novel compounds
MXPA05011497A (es) Derivados de tropano y su uso como inhibidores de la enzima de conversion de angiotensina (ace).
TW200604173A (en) Novel compounds
MXPA05008314A (es) Derivados de 8-aza-biciclo[3.2.1]octano y su uso como inhibidores de reabsorcion del neurotransmisor de monoamina.
MX2010001075A (es) Derivados de n-piperidin-4-ilmetil-amida y su uso como inhibidores de recaptacion del neurotransmisor de monoamina.
TW200621773A (en) Bicyclononene derivatives
PL375163A1 (en) Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
MX2009006213A (es) Nuevos derivados de cromen-2-ona y su uso como inhibidores de reabsorcion del neurotransmisor monoamina.
NO20055749L (no) Sulfamat benzotiofenderivater som steroid sulfatase inhibitorer
BRPI0519921A2 (pt) composto enanciopuro ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica,e, uso de composto quìmico ou de um sal farmaceuticamente aceitável do mesmo
MY140105A (en) 2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts
WO2006075004A3 (en) 3, 8 - substituted 8-aza-bicyclo[3.2.1] octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
MX2007002384A (es) Nuevos derivados de cromen-2-ona y su uso como inhibidores de la reabsorcion del neurotransmisor de monoamina.
DK1638948T3 (da) Diphenylurinstofderivater og deres anvendelse som chloridkanalblokkere
HRP20050603A2 (en) Novel anticonvulsant derivative salts
TW200603803A (en) Novel compounds
TW200621774A (en) Bicyclononene derivatives
TW200504017A (en) Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors